Prestige Brands Holdings, Inc. — FY2015 Form 10-K
Entity and period: The filing is for Prestige Brands Holdings, Inc. (not a company named Prestige Consumer Healthcare) and covers the fiscal year ended March 31, 2015. It is an annual report, not a stand-alone fourth-quarter filing; quarterly information is included.
Business context and results
The company markets and distributes OTC healthcare and household-cleaning brands through three segments: North American OTC Healthcare, International OTC Healthcare, and Household Cleaning. Growth is substantially acquisition-led. During FY2015, it acquired Insight Pharmaceuticals for $753.2 million and the Hydralyte brand for approximately $78.0 million.
| Metric | FY2015 | FY2014 | Change |
|---|---|---|---|
| Total revenue | $714.6 million | $597.4 million | +19.6% |
| Gross profit / margin | $406.2 million / 56.8% | $335.6 million / 56.2% | Margin +0.6 percentage points |
| Operating income / margin | $207.6 million / 29.0% | $188.6 million / 31.6% | Income +10.0%; margin lower |
| Net income | $78.3 million | $72.6 million | +7.8% |
| Diluted EPS | $1.49 | $1.39 | +7.2% |
| Operating cash flow | $156.3 million | $111.6 million | +$44.7 million |
| Capital expenditures | $6.1 million | $2.8 million | +$3.3 million |
Financial position and material changes
- Revenue growth reflected the acquired Insight and Hydralyte businesses. North American OTC revenue rose 17.5%; international OTC revenue rose 104.5%; household-cleaning revenue increased 2.5%.
- Acquisition-related compensation, transaction, and professional costs contributed to general and administrative expense increasing to $81.3 million from $48.5 million. Net interest expense rose to $81.2 million from $68.6 million as average debt increased, partly offset by a lower average borrowing cost.
- Cash and cash equivalents were $21.3 million at March 31, 2015, versus $28.3 million a year earlier. Current assets were $201.7 million and current liabilities $99.0 million. Cash flow from operations improved; investing cash outflow of $805.3 million was primarily acquisition-related.
- Total debt was $1,593.6 million, up from $937.5 million. The company reported $44.9 million of available capacity on its revolving credit facility and was in compliance with its debt covenants at year-end. Debt includes $650.0 million of senior notes and variable-rate term loans and revolver borrowings.
- Goodwill and intangible assets totaled $2.43 billion, approximately 91% of total assets. No impairment charge was recorded, but the filing identifies certain trade names with fair value less than 10% above carrying value.
Outlook, risks, and unusual items
- The filing provides no formal numeric revenue or earnings guidance. Management expects to fund operations over the next 12 months with operating cash flows and borrowings, and anticipated covenant compliance in FY2016.
- Management cited supply constraints affecting women’s-health products and said alternative manufacturing and ingredient suppliers were being pursued. Some manufacturers were also struggling to meet demand for popular products; delays could reduce sales.
- Key risks include high debt and interest-rate exposure, customer concentration (Walmart represented 18.1% of FY2015 gross revenue), dependence on third-party manufacturers, competitive and private-label pressure, regulatory and product-liability matters, and possible impairment of acquired brands. A 1 percentage-point increase in rates on variable-rate debt was estimated to reduce annual pretax earnings and cash flow by about $7.2 million.
- FY2015 included a $1.1 million gain on selling certain Comet trademark rights. The effective tax rate increased to 38.6% from 28.6%, reflecting acquisition-related nondeductible items and the absence of a prior-year $9.1 million state-tax benefit. Currency translation reduced comprehensive income by $24.2 million.
- After year-end, the company refinanced term loans in May 2015, lowering the stated LIBOR margin on the consolidated term-loan class. It also announced that CEO Matthew Mannelly would retire effective June 1, 2015, with CFO Ronald Lombardi named successor CEO while remaining CFO pending a search.
- The auditor issued an unqualified opinion and concluded internal control over financial reporting was effective as of March 31, 2015. The filing discloses evaluation of a product-registration failure that could lead to temporary sales discontinuation, and a minor product recall.
Most important facts for investors to verify
- How much FY2015 growth and future earnings are attributable to acquired brands versus organic performance, and whether Insight integration delivers expected benefits.
- Whether women’s-health supply and manufacturing constraints are resolved and whether product availability supports demand.
- Debt repayment capacity, covenant headroom, variable-rate exposure, and the terms and completion of the post-year-end refinancing and revolver amendment.
- Performance and impairment assumptions for Pediacare, Debrox, New-Skin, Ecotrin, and other brands with recent declines or narrow valuation cushions.
- Customer concentration, product-return and promotional estimates, and the status and financial exposure of regulatory, recall, and other contingencies.